Updated Evaluation of the Safety, Efficacy and Tolerability of Tafamidis in the Treatment of Hereditary Transthyretin Amyloid Polyneuropathy

References

• Adams D, Koike H, Slama M, Coelho T. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol. 2019;15(7):387–404. doi:10.1038/s41582-019-0210-4
   PubMed Web of Science ®Google Scholar
• Parman Y, Adams D, Obici L, et al. From the European Network for TTR-FAP (ATTReuNET), Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP. Curr Opin Neurol. 2016;29(Suppl 1):S3–S13. doi:10.1097/WCO.0000000000000288
   PubMed Web of Science ®Google Scholar
• Sekijima Y. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry. 2015;86(9):1036–1043. doi:10.1136/jnnp-2014-308724
   PubMed Web of Science ®Google Scholar
• Carroll A, James Dyck P, de Carvalho M, et al. 10. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis. J Neurol Neurosurg Psychiatry. 2022;93(6):668–678. doi:10.1136/jnnp-2021-327909
   PubMedGoogle Scholar
• Ericzon BG, Wilezek HE, Larsson M, et al. Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation. 2015;99(9):1847–1854. doi:10.1097/TP.0000000000000574
   PubMed Web of Science ®Google Scholar
• Carvalho A, Rocha A, Lobato L, et al. Liver transplantation in transthyretin amyloidosis: issues and challenges. Liver Transpl. 2015;21(3):282–292. doi:10.1002/lt.24058
   PubMed Web of Science ®Google Scholar
• Burton A, Castaño A, Bruno M, et al. Drug discovery and development in rare disease: taking a closer look at the Tafamidis story. Drug Des Devel Ther. 2021;15:1225–1243. doi:10.2147/DDDT.S289772
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Vyndaqel (tafamidis) 20 mg soft capsules: summary of product characteristics; 2016. Available from: http://www.ema-europa.eu/. Accessed August 10, 2022.
   Google Scholar
• Adams D, Gonzalez-Duarte A, O’Riordan W, et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018;379:11–21. doi:10.1056/NEJMoa1716153
   PubMed Web of Science ®Google Scholar
• Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:22–31. doi:10.1056/NEJMoa1716793
   PubMed Web of Science ®Google Scholar
• Buxbaum JN, Reixach N. Transthyretin: the servant of many masters. Cell Mol Life Sci. 2009;66:3095–3101. doi:10.1007/s00018-009-0109-0
   PubMed Web of Science ®Google Scholar
• Johnson SM, Connelly S, Fearns C, et al. The transthyretin amyloidosis: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol. 2012;421:185–203. doi:10.1016/j.jmb.2011.12.060
   PubMed Web of Science ®Google Scholar
• Johnson SM, Wiseman RL, Sekijima Y, et al. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidosis. Acc Chem Res. 2005;38:911–921. doi:10.1021/ar020073i
   PubMed Web of Science ®Google Scholar
• Berk J, Dyck P, Obici L, et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid. 2011;18(1):191–192. doi:10.3109/13506129.2011.574354073
   PubMedGoogle Scholar
• Bulawa CE, Connely S, DeVit M, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. PNAS. 2012;24:9629–9634. doi:10.1073/pnas.1121005109
   Google Scholar
• Coelho T, Merlini G, Bulawa CE, et al. Mechanism of action and clinical application of tafamidis in hereditary transthyretin amyloidosis. Neurol Ther. 2016;5:1–25. doi:10.1007/s40120-016-0040-x
   PubMed Web of Science ®Google Scholar
• Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785–792. doi:10.1212/WNL.0b013e3182661eb1
   PubMed Web of Science ®Google Scholar
• Coelho T, Maia LF, Martins da Silva A, et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol. 2013;260(11):2802–2814. doi:10.1007/s00415-013-7051-7
   PubMed Web of Science ®Google Scholar
• Barroso FA, Judge DP, Ebede D, et al. Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. Amyloid. 2017;24(3):194–204. doi:10.1080/13506129.2017.1357545
   PubMed Web of Science ®Google Scholar
• Merlini G, Judge DP. P-B, Judge DP, et al. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Trans Res. 2013;6(6):1011–1020. doi:10.1007/s12265-013-9512-x
   PubMed Web of Science ®Google Scholar
• Ando Y, Sekijima Y, Obayashi K, et al. Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: a phase III, open-label study. J Neurol Sci. 2016;362:266–271. doi:10.1016/j.jns.2016.01.046
   PubMed Web of Science ®Google Scholar
• Merlini G, Coelho T, Cruz W, Li H, Stewart M, Ebede B. Evaluation of mortality during long-term treatment with tafamidis for transthyretin amyloidosis with polyneuropathy: the clinical trial results up to 8.5 years. Neurol Ther. 2020;9(1):105–115. doi:10.1007/s40120-020-00180-w
   PubMed Web of Science ®Google Scholar
• Keohane D, Schwartz J, Gundapaneni B, et al. Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analysis from the pivotal trial. Amyloid. 2017;24(1):30–36. doi:10.1080/13506129.2017.1301419
   PubMed Web of Science ®Google Scholar
• Waddington Cruz M, Amass L, Keohane D, et al. Early intervention with tafamidis provides long-term (5.5 years) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy. Amyloid. 2016;23(3):178–183. doi:10.1080/13506129.2016.1207163
   PubMed Web of Science ®Google Scholar
• Amass L, Li H, Gundapaneni B, et al. Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy. Orphanet J Rare Dis. 2018;13:225. doi:10.1186/s13023-018-0947-7
   PubMed Web of Science ®Google Scholar
• Suhr OB, Conceição IM, Karayal ON, et al. Post Hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurol Ther. 2014;3(2):101–112. doi:10.1007/s40120-014-0023-8
   PubMedGoogle Scholar
• Gundapaneni BK, Sultan MB, Keokane DJ, et al. Tafamidis delays neurological progression comparably across Val30Met and non-Val30Met genotypes in transthyretin familial amyloid polyneuropathy. Eur J Neurol. 2018;25(3):464–468. doi:10.1111/ene.13510
   PubMed Web of Science ®Google Scholar
• Ungerer MN, Hund E, Ourrucker JC, et al. Real-world outcomes in non-endemic hereditary transthyretin amyloidosis with polyneuropathy: a 20-year German single-referral centre experience. Amyloid. 2021;28(2):91–99. doi:10.1080/13506129.2020.1855134
   PubMed Web of Science ®Google Scholar
• Plante-Bordeneuve V, Suhr OB, Maurer MS, et al. The Transthyretin Amyloidosis Outcomes Survey (THAOS) registry: design and methodology. Curr Med Res Opin. 2013;29(1):77–84. doi:10.1185/03007995.2012.754349
   PubMed Web of Science ®Google Scholar
• Mundayat R, Stewart M, Alvir J, et al. Positive effectiveness of tafamidis in delaying disease progression in transthyretin familial amyloid polyneuropathy up to 2 years: an analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS). Neurol Ther. 2018;7(1):87–101. doi:10.1007/s40120-018-0097-9
   PubMed Web of Science ®Google Scholar
• Cortese A, Vita G, Luigetti M, et al. Monitoring effectiveness and safety of tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicentre study in a non-endemic area. J Neurol. 2016;263(5):916–924. doi:10.1007/s00415-016-8064-9
   PubMed Web of Science ®Google Scholar
• Plante-Bordeneuve V, Gorram F, Salhi H, et al. Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study. J Neurol. 2017;264(2):269–276. doi:10.1007/s00415-016-8337-3
   Web of Science ®Google Scholar
• Monteiro C, Mesgazardeh JS, Anselmo J, et al. Predictive model of response to tafamidis in hereditary ATTR polyneuropathy. JCI Insight. 2019;4(12):e126526. doi:10.1172/jci.insight.126526
   PubMed Web of Science ®Google Scholar
• Huber P, Flynn A, Suktan MB, et al. A comprehensive safety profile of tafamidis in patients with transthyretin amyloid polyneuropathy. Amyloid. 2019;26(4):203–209. doi:10.1080/13506129.2019.1643714
   PubMed Web of Science ®Google Scholar
• Ishii T, Hirano Y, Matsumoto N, et al. Characteristics of patients with hereditary transthyretin amyloidosis and an evaluation of the safety of tafamidis meglumine in Japan: an interim analysis of an all-case post marketing surveillance. Clin Ther. 2020;42(9):1728–1737. doi:10.1016/j.clinthera.2020.07.001
   PubMed Web of Science ®Google Scholar
• Pfizer Ltd. VyndaqelVR summary of product characteristics. [Internet]. Sandwich, UK. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Product_Information/human/002294/WC500117862.pdf. Accessed January 26, 2023.
   Google Scholar
• Waddington CM, Benson MD. A review of tafamidis for the treatment of Transthyretin-related amyloidosis. Neurol Ther. 2015;4:61–79. doi:10.1007/s40120-015-0031-3
   PubMedGoogle Scholar
• Lamb YN, Deeks ED. Tafamidis: a review in transthyretin amyloidosis with polyneuropathy. Drugs. 2019;79:863–874. doi:10.1007/s40265-019-01129-6
   PubMed Web of Science ®Google Scholar
• Adams D, Suhr OB, Hund E, et al. First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol. 2016;29(Suppl1):S14–S26. doi:10.1097/WCO.0000000000000289
   PubMedGoogle Scholar
• Barbosa da Silva RV, Cruz MW, Planté-Bordeneuve V. Follow-up of transthyretin amyloidosis patients with liver transplants or receiving tafamidis treatment as documented in THAOS: the transthyretin amyloidosis outcomes survey. Poster presented at the 16th Congress of The European Federation of Neurological Societies; Stockholm, Sweden; 2012: P2918.
   Google Scholar
• Coelho T, Inês M, Conceição I, et al. Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy. Neurology. 2018;91(21):e1999–e2009. doi:10.1212/WNL.0000000000006543
   PubMed Web of Science ®Google Scholar
• Sekijima Y, Ueda M, Koike H, et al. Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm. Orphanet J Rare Dis. 2018;13(1):6. doi:10.1186/s13023-017-0726-x
   PubMed Web of Science ®Google Scholar
• Coelho T. Disease Modifying Therapies for ATTR Amyloidoses: Clinical Development of New Drugs and Impact on the Natural History of the Disease. D.ICBAS; 2019.
   Google Scholar
• Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007–1016. doi:10.1056/NEJMoa1805689
   PubMed Web of Science ®Google Scholar
• Conceição I, González-Duarte A, Obici L, et al. “Red-flag” symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst. 2016;21(1):5–9. doi:10.1111/jns.12153
   PubMed Web of Science ®Google Scholar
• Adams D, Ando Y, Beirão JM, et al. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol. 2021;268(6):2109–2122. doi:10.1007/s00415-019-09688-0
   PubMed Web of Science ®Google Scholar
• Conceição I, Damy T, Romero M, et al. Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations. Amyloid. 2019;26(1):3–9. doi:10.1080/13506129.2018.1556156
   PubMed Web of Science ®Google Scholar
• Lladó L, Baliellas C, Casasnovas C, et al. Risk of transmission of systemic transthyretin amyloidosis after domino liver transplantation. Liver Transpl. 2010;16(12):1386–1392. doi:10.1002/lt.22174
   PubMed Web of Science ®Google Scholar
• Liepnieks JJ, Zhnag LQ, Benson MD. Progression of transthyretin amyloid neuropathy after liver transplantation. Neurology. 2010;75(4):324–327. doi:10.1212/WNL.0b013e3181ea15d4
   PubMed Web of Science ®Google Scholar
• Sousa L, Coelho T, Taipa R. CNS involvement in hereditary transthyretin amyloidosis. Neurology. 2021;97(24):1111–1119. doi:10.1212/WNL.0000000000012965
   PubMed Web of Science ®Google Scholar
• Minnella AG, Risotto R, Antoniazzi E, et al. Ocular involvement in hereditary amyloidosis. Genes. 2021;12(7):955. doi:10.3390/genes12070955
   PubMed Web of Science ®Google Scholar
• Monteiro C, Martins da Silva A, Ferreira N, et al. Cerebrospinal fluid and vitreous body exposure to orally administered tafamidis in hereditary ATTRV30M (p.TTRV50M) amyloidosis patients. Amyloid. 2018;25(2):120–128. doi:10.1080/13506129.2018.1479249
   PubMed Web of Science ®Google Scholar
• Casal I, Monteiro S, Beirão JM. Tafamidis in hereditary ATTR amyloidosis – our experience on monitoring the ocular manifestations. Amyloid. 2016;23(4):262–263. doi:10.1080/13506129.2016.1236332
   PubMed Web of Science ®Google Scholar